Cannabis Equities Retreat as U.S. Reclassification Hopes Fade

Shares of leading cannabis operators, including Cronos Group (CRON), Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), and Organigram (OGI), reversed early gains on Thursday. The sell-off followed a period of optimism regarding federal regulatory shifts in the United States. The volatility stems from a reassessment of the U.S. government's decision to reclassify FDA-approved and state-licensed marijuana as a lower-risk drug. While initially viewed as a catalyst for growth, market participants now perceive the scope of this reclassification as too narrow to drive a broad industry recovery. This reversal indicates a 'sell the news' reaction, where the actual policy details failed to meet the high expectations baked into the early morning price action. Traders are focusing on the limited nature of the FDA-approved criteria, which may exclude many current commercial operations. The sector remains highly sensitive to federal policy changes, but the current trend suggests that incremental regulatory steps may not be sufficient to offset the structural challenges facing cannabis firms.